高级检索
当前位置: 首页 > 详情页

Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Neurology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. [2]Department of Neurology, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China. [3]Department of Reproductive Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. [4]Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. [5]Department of Infectious Diseases, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
出处:
ISSN:

关键词: non-small cell lung cancer (NSCLC) leptomeningeal metastases (LM) brain parenchyma metastases (BPM) cerebrospinal fluid circulating tumour DNA (ctDNA) next generation sequencing

摘要:
Brain metastases (BM), including brain parenchyma metastases (BPM) and leptomeningeal metastases (LM), are devastating metastatic complications in advanced cancer patients. Next-generation sequencing (NGS) is emerging as a new promising tool for profiling cancer mutation, which could facilitate the diagnosis of cancer. This retrospective study aimed to investigate the molecular genetic characteristics of non-small cell lung cancer (NSCLC) patients with BPM and LM using NGS.Cerebrospinal fluid (CSF) samples and paired plasma samples were collected from 37 patients of NSCLC-BM. We profiled genetic mutation characteristics using NGS from NSCLC-BM by comparing CSF circulating tumour DNA (ctDNA) with plasma ctDNA and primary tumour tissues.Among the 37 patients with NSCLC-BM, 28 patients had LM with or without BPM, while 9 patients only had BPM. Driver and drug-resistant mutations in primary tumours with LM included: EGFR L858R (10, 35.7%), EGFR 19del (6, 21.4%), EGFR L858R+MET (1, 3.6%), EGFR L858R+S768I (1, 3.6%), ALK (2, 7.1%), ROS1 (1, 3.6%), negative (5, 17.9%), and unknown (2, 7.1%). In patients with NSCLC-LM, the detection rate and abundance of ctDNA in the CSF were significantly higher than those in paired plasma. The main driver mutations of NSCLC-LM remained highly consistent with those of the primary tumours, along with other unique mutations. Circulating tumour DNA was negative in the CSF samples of BPM patients. Patients with BMP had a higher ratio of EGFR 19del than L858R mutation (55.6% vs 11.1.%), whereas NSCLC patients with LM had a higher ratio of EGFR L858R than 19del mutation (50.0% vs 25.0%). Most patients with positive plasma ctDNA results were male (p = 0.058) and in an unstable state (p = 0.003).Our study indicated that the CSF ctDNA detected by NGS may reflect the molecular characteristics and heterogeneity of NSCLC-LM. Timely screening of patients with NSCLC for CSF ctDNA, especially for patients with positive plasma ctDNA, may facilitate the early detection of LM. Furthermore, patients with the EGFR 19del may have a higher risk of developing BPM.Copyright © 2024 Liu, Mei, Fang, Jia, Zhou, Li, Tian, Lu and Li.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2024]版:
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Department of Neurology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. [2]Department of Neurology, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China.
通讯作者:
通讯机构: [4]Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. [5]Department of Infectious Diseases, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号